Developer docs
API playgroundTry for free, no card

Search company profiles

Advicenne

Full company profile

uuid0002vd8

Namestring
Advicenne
Legal namestring
Advicenne
Websiteurl
advicenne.com
Company typeenum
Public
Founded yearint
2017
Descriptiontext

Advicenne is a Paris-based specialty pharmaceutical company founded in 2007 and listed on Euronext Growth Paris (ticker: ALDVI) since March 2022, focused on developing and commercializing treatments for rare kidney diseases and niche pediatric neurology indications. Its lead product, Sibnayal® (ADV7103), is a prolonged-release granule formulation combining potassium citrate and potassium bicarbonate for the treatment of distal Renal Tubular Acidosis (dRTA) in both children and adults. Sibnayal® received European Commission approval in May 2021 and MHRA approval in July 2021, making it the first approved treatment for dRTA in Europe and the UK. The product is commercially available across most of Europe (France, UK, Germany, Denmark, Italy, Spain, Portugal, Nordics) and the Middle East (Saudi Arabia, UAE) through a hybrid model combining direct sales in core markets with exclusive distribution partnerships (FrostPharma AB, Taïba Healthcare, SPA, Avanzanite Bioscience). A second commercial product, Likozam® (clobazam) for drug-resistant pediatric epilepsy, received French reimbursement in June 2026, and a cystinuria indication for ADV7103 is in clinical development with FDA Orphan Drug Designation granted in March 2024.

The company generates revenue through product sales (€5.79 million in 2025, up 18.7% YoY), royalty income from divested/licensed products (€1.1 million in 2025), and licensing agreements, with pricing set via national reimbursement systems. R&D, clinical, and regulatory activities are coordinated from Paris with US operations supporting the FDA NDA process; FDA accepted the Sibnayal® dRTA NDA for review in January 2026 with a decision expected by September 2026. The company holds Orphan Drug Designations from both the EMA and FDA for ADV7103 in dRTA and cystinuria, and has secured over €33 million in cumulative financing through EIB debt tranches, state-guaranteed loans, and equity placements.

Financially, Advicenne is in a critical transition phase: 2025 net loss widened to €9.53 million (from €6.47 million in 2024) due to elevated R&D spending and pharmaceutical taxes, and the year-end 2025 cash position was only €1.35 million. In May 2026 the company opened safeguard proceedings to restructure its liabilities, followed by a €3.8 million bond financing in June 2026 extending cash runway to Q2 2027. Revenue concentration remains moderate, with Sibnayal® as the dominant product and heavy reliance on French and UK reimbursement systems for pricing and access.

Short descriptiontext

Advicenne is a Paris-based specialty pharmaceutical company developing and commercializing pediatric-friendly treatments for rare renal diseases (Sibnayal® for dRTA) and pediatric epilepsy (Likozam®), serving patients across Europe and the Middle East with FDA review pending in the US.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersParis, France
HQ citystring
Paris
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
rare disease therapeutics, pediatric renal formulations, orphan drug pharmaceuticals, specialty nephrology drugs, renal tubular acidosis treatment
Industry4 codes
PRIMARYHLAIAIAI
Rare Renal & Nephrology Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAKAHAL
Renal Nutrition & Kidney Dietetics Services
SECONDARYHLAKAHAH
Pediatric Nephrology
SECONDARYHLAIACAH
Nephrology & Urology Specialty Pharmaceuticals
NAICS code1 code
  • Kidney Dialysis Centers621492
SIC code1 code
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Specialty Pharmaceuticals - Rare Renal Disease Therapeutics
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Product Sales - Sibnayal®
TypeOne Time License
Description

Direct product sales of Sibnayal® for dRTA treatment across European markets (France, UK, Germany, Denmark, Italy, Spain, Portugal, Nordic countries, Saudi Arabia, UAE). Revenue generated through pharmacy dispensing with official reimbursement in multiple countries.

advicenne.com
2Product Sales - Likozam®
TypeOne Time License
Description

Sales of Likozam® (clobazam) for drug-resistant epilepsy in France, with reimbursement from French social security system at €92.24 per 150ml bottle.

pharmiweb.com
3Royalties
TypeLicensing Royalties
Description

Royalty income from licensed products including ADV6209 sold to Primex Pharmaceuticals AG. Royalties doubled to €1.1 million in 2025.

pharmiweb.com
4Out-licensing - Levidcen
TypeLicensing Royalties
Description

License agreement with Desitin for anti-epileptic Levidcen micro-granules for French market.

advicenne.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels7 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations
Pricing details1 tier
1Likozam® 150ml bottle reimbursement price
ModelOtherBilling cadencePay-as-you-go
Notes

Reimbursement price of €92.24 per 150ml bottle generates receivable that offsets approximately €6 million in debt owed to French government.

businesswire.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Sibnayal®
Description

Lead product (ADV7103) - combination of Potassium citrate and Potassium bicarbonate for treatment of distal Renal Tubular Acidosis (dRTA). Approved by EMA and MHRA in 2021.

advicenne.com
+2 more records
Core offering1 text field

Advicenne develops and commercializes pediatric-friendly specialty pharmaceutical products for rare renal diseases, with lead product Sibnayal® (ADV7103), a prolonged-release granule formulation combining potassium citrate and potassium bicarbonate approved in Europe and the UK for treating distal Renal Tubular Acidosis (dRTA) in children and adults. The portfolio also includes Likozam® (clobazam) for drug-resistant pediatric epilepsy, with pipeline expansion into cystinuria via ADV7103.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • European end-market sales of Sibnayal® surged 71% to €10.8 million in 2025
+3 more records
Product overview1 text field

Advicenne is a specialty pharmaceutical company dedicated to developing and commercializing pediatric-friendly therapeutics for the treatment of orphan renal diseases and niche neurology indications. The company's primary commercial product is Sibnayal® (ADV7103), a combination of potassium citrate and potassium bicarbonate approved in 2021 for treating distal Renal Tubular Acidosis (dRTA) in Europe and the UK, with FDA review ongoing in the United States. The product portfolio also includes Likozam® (clobazam) for drug-resistant epilepsy in children, which received French reimbursement in 2026. The pipeline includes ADV7103 for cystinuria treatment. The company operates from Paris, France, and is listed on Euronext Growth (ALDVI).

Product and service3 records
1Sibnayal® (ADV7103)
CategorySpecialty Pharmaceutical - Rare Renal Disease Therapeutic
Description

A prolonged-release granule formulation combining potassium citrate and potassium bicarbonate for the treatment of distal Renal Tubular Acidosis (dRTA) in adults and children. Approved by the European Medicines Agency (2021) and UK MHRA (2021); under FDA review in the United States. Available in 8 mEq and 24 mEq doses.

2Likozam® (clobazam)
CategorySpecialty Pharmaceutical - Pediatric Neurology Therapeutic
Description

An anti-epileptic medication (clobazam) primarily used for the treatment of drug-resistant epilepsy in children. Reimbursed in France at €92.24 per 150ml bottle through the French social security system.

3ADV7103 for Cystinuria
CategorySpecialty Pharmaceutical - Rare Renal Disease Pipeline
Description

Pipeline extension of ADV7103 in development for the treatment of cystinuria, a rare inherited cystine transport disorder causing recurrent kidney stones. Granted FDA Orphan Drug Designation in March 2024.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierMinorTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2024-12-13
Description

Agreement finalized December 2024 for previously sold drug candidate ADV6209 (for moderate sedation). Generates ongoing royalty income.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-02-28
Description

Distribution agreement completing European commercial coverage of Sibnayal®, specifically for Germany. Finalizes full European geographic footprint.

3SPA (Società Prodotti Antibiotici)
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-02-14
Description

Exclusive distribution agreement for marketing of Sibnayal® in Italy, Spain, and Portugal. Strategic partnership for Southern European market coverage.

advicenne.com
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2022-06-28
Description

Commercialization agreement for Sibnayal® in Middle-East region. Enables patient access in Saudi Arabia (marketing authorization and reimbursement received July 2025) and UAE (January 2026).

5FrostPharma AB
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2022-01-04
Description

Exclusive distribution partnership for commercialization of Sibnayal™ in the Nordic region (Denmark, Norway, Sweden, Finland, Iceland). Enables market access in Nordic countries through established local pharmaceutical distribution.

advicenne.com
6Elaiapharm Lundbeck
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2019-09-04
Description

Long-term manufacturing supply agreement securing production of ADV7103. Ensures reliable supply chain for commercial production of Sibnayal®.

advicenne.com
7European Society for Paediatric Nephrology (ESPN)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2018-05-15
Description

Partnership to improve patient care for distal Renal Tubular Acidosis (dRTA) in Europe. Aims to enhance knowledge and management of the disease through scientific collaboration.

advicenne.com
Strategic tierMinorTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2014-02-20
Description

License agreement on anti-epileptic Levidcen micro-granules for French market. Product authorized for marketing in France April 2015.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Established US rare disease specialty pharma with a portfolio of orphan therapies across multiple indications. Comparable as a larger, commercially mature rare disease player pursuing similar regulatory and reimbursement pathways.

TypeDirect peer
Description

US rare-disease specialty pharma with a focused rare kidney disease portfolio (FILSPARI for IgA nephropathy, sparsentan). Comparable to Advicenne as a small-cap rare renal player pursuing orphan indications and navigating similar commercial and regulatory milestones.

TypeBroad incumbent
Description

Commercial-stage rare disease biotech with multiple approved orphan therapies and a focus on smaller populations. Comparable in business model, regulatory pathway expertise, and commercial-stage rare disease focus.

TypeEmerging player
Description

Rare kidney disease biotech (acquired by Novartis in 2023) that developed therapies for IgA nephropathy and other rare renal conditions. Comparable as a focused rare renal disease developer that pursued similar orphan nephrology indications.

TypeDirect peer
Description

US specialty pharmaceutical company with products in nephrology and related therapeutic areas. Comparable as a smaller specialty pharma with focused renal/urology commercial offerings and similar distribution-driven commercial model.

TypeDirect peer
Description

Swedish specialty pharma that developed Tarpeyo, the first FDA-approved treatment for IgA nephropathy. Highly comparable as a small European-headquartered rare renal disease company commercializing an orphan kidney therapy in the US and EU.

TypeBroad incumbent
Description

Global rare disease franchise within AstraZeneca with established renal and metabolic rare disease therapies (e.g., complement-mediated kidney disorders). Comparable as a broader incumbent that overlaps with Advicenne's nephrology rare disease focus.

TypeBroad incumbent
Description

Established Japanese pharmaceutical company that developed JYNARQUE (tolvaptan) for autosomal dominant polycystic kidney disease (ADPKD). Comparable as a large incumbent with a meaningful rare renal franchise overlapping Advicenne's nephrology focus.

TypeDirect peer
Description

Swedish-headquartered rare disease specialty pharma commercializing across Europe and the US. Comparable in business model (rare disease focus, European-listed, commercial-stage) and in serving similar small-population specialty indications.

TypeDirect peer
Description

The rare disease division of Recordati, focused on specialty and orphan therapies across multiple geographies. Comparable to Advicenne as a Europe-based specialty pharma commercializing orphan therapeutics via partner-driven distribution.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries5 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Advicenne

Specialty Pharmaceuticals - Rare Renal Disease Therapeuticsadvicenne.com

Advicenne is a Paris-based specialty pharmaceutical company developing and commercializing pediatric-friendly treatments for rare renal diseases (Sibnayal® for dRTA) and pediatric epilepsy (Likozam®), serving patients across Europe and the Middle East with FDA review pending in the US.

What Advicenne does

Advicenne is a Paris-based specialty pharmaceutical company founded in 2007 and listed on Euronext Growth Paris (ticker: ALDVI) since March 2022, focused on developing and commercializing treatments for rare kidney diseases and niche pediatric neurology indications. Its lead product, Sibnayal® (ADV7103), is a prolonged-release granule formulation combining potassium citrate and potassium bicarbonate for the treatment of distal Renal Tubular Acidosis (dRTA) in both children and adults. Sibnayal® received European Commission approval in May 2021 and MHRA approval in July 2021, making it the first approved treatment for dRTA in Europe and the UK. The product is commercially available across most of Europe (France, UK, Germany, Denmark, Italy, Spain, Portugal, Nordics) and the Middle East (Saudi Arabia, UAE) through a hybrid model combining direct sales in core markets with exclusive distribution partnerships (FrostPharma AB, Taïba Healthcare, SPA, Avanzanite Bioscience). A second commercial product, Likozam® (clobazam) for drug-resistant pediatric epilepsy, received French reimbursement in June 2026, and a cystinuria indication for ADV7103 is in clinical development with FDA Orphan Drug Designation granted in March 2024.

The company generates revenue through product sales (€5.79 million in 2025, up 18.7% YoY), royalty income from divested/licensed products (€1.1 million in 2025), and licensing agreements, with pricing set via national reimbursement systems. R&D, clinical, and regulatory activities are coordinated from Paris with US operations supporting the FDA NDA process; FDA accepted the Sibnayal® dRTA NDA for review in January 2026 with a decision expected by September 2026. The company holds Orphan Drug Designations from both the EMA and FDA for ADV7103 in dRTA and cystinuria, and has secured over €33 million in cumulative financing through EIB debt tranches, state-guaranteed loans, and equity placements.

Financially, Advicenne is in a critical transition phase: 2025 net loss widened to €9.53 million (from €6.47 million in 2024) due to elevated R&D spending and pharmaceutical taxes, and the year-end 2025 cash position was only €1.35 million. In May 2026 the company opened safeguard proceedings to restructure its liabilities, followed by a €3.8 million bond financing in June 2026 extending cash runway to Q2 2027. Revenue concentration remains moderate, with Sibnayal® as the dominant product and heavy reliance on French and UK reimbursement systems for pricing and access.

Advicenne firmographics

Firmographics
Name
Advicenne
Legal name
Advicenne
Website
https://advicenne.com
Company type
Public
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
Advicenne is a Paris-based specialty pharmaceutical company developing and commercializing pediatric-friendly treatments for rare renal diseases (Sibnayal® for dRTA) and pediatric epilepsy (Likozam®), serving patients across Europe and the Middle East with FDA review pending in the US.
Ownership category
akta.pro rank

Advicenne industry classification

Industry
Product category
Specialty Pharmaceuticals - Rare Renal Disease Therapeutics
NAICS
Kidney Dialysis Centers (621492)
SIC
Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYHLAIAIAI
Rare Renal & Nephrology Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAKAHAL
Renal Nutrition & Kidney Dietetics Services
SECONDARYHLAKAHAH
Pediatric Nephrology
SECONDARYHLAIACAH
Nephrology & Urology Specialty Pharmaceuticals

Keywords

  • Rare disease therapeutics
  • Pediatric renal formulations
  • Orphan drug pharmaceuticals
  • Specialty nephrology drugs
  • Renal tubular acidosis treatment

Where Advicenne is headquartered

Location

Headquarters

HQ city
Paris
HQ country
France
HQ region
Europe

Offices3 records

Markets served

Advicenne business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations

Revenue model

  1. Product Sales - Sibnayal®: Direct product sales of Sibnayal® for dRTA treatment across European markets (France, UK, Germany, Denmark, Italy, Spain, Portugal, Nordic countries, Saudi Arabia, UAE). Revenue generated through pharmacy dispensing with official reimbursement in multiple countries.
  2. Product Sales - Likozam®: Sales of Likozam® (clobazam) for drug-resistant epilepsy in France, with reimbursement from French social security system at €92.24 per 150ml bottle.
  3. Royalties: Royalty income from licensed products including ADV6209 sold to Primex Pharmaceuticals AG. Royalties doubled to €1.1 million in 2025.
  4. Out-licensing - Levidcen: License agreement with Desitin for anti-epileptic Levidcen micro-granules for French market.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goLikozam® 150ml bottle reimbursement price

Go-to-market motion3 records

Distribution channels7 records

Marketing channels5 records

Advicenne product offering

Product offering

Core offering

Advicenne develops and commercializes pediatric-friendly specialty pharmaceutical products for rare renal diseases, with lead product Sibnayal® (ADV7103), a prolonged-release granule formulation combining potassium citrate and potassium bicarbonate approved in Europe and the UK for treating distal Renal Tubular Acidosis (dRTA) in children and adults. The portfolio also includes Likozam® (clobazam) for drug-resistant pediatric epilepsy, with pipeline expansion into cystinuria via ADV7103.

Product overview

Advicenne is a specialty pharmaceutical company dedicated to developing and commercializing pediatric-friendly therapeutics for the treatment of orphan renal diseases and niche neurology indications. The company's primary commercial product is Sibnayal® (ADV7103), a combination of potassium citrate and potassium bicarbonate approved in 2021 for treating distal Renal Tubular Acidosis (dRTA) in Europe and the UK, with FDA review ongoing in the United States. The product portfolio also includes Likozam® (clobazam) for drug-resistant epilepsy in children, which received French reimbursement in 2026. The pipeline includes ADV7103 for cystinuria treatment. The company operates from Paris, France, and is listed on Euronext Growth (ALDVI).

Differentiator

Problem solved

Functional benefit

Brands

  • Sibnayal®: Lead product (ADV7103) - combination of Potassium citrate and Potassium bicarbonate for treatment of distal Renal Tubular Acidosis (dRTA). Approved by EMA and MHRA in 2021.
  • Likozam®
  • Levidcen

Products and services

  • Sibnayal® (ADV7103) A prolonged-release granule formulation combining potassium citrate and potassium bicarbonate for the treatment of distal Renal Tubular Acidosis (dRTA) in adults and children. Approved by the European Medicines Agency (2021) and UK MHRA (2021); under FDA review in the United States. Available in 8 mEq and 24 mEq doses.
  • Likozam® (clobazam) An anti-epileptic medication (clobazam) primarily used for the treatment of drug-resistant epilepsy in children. Reimbursed in France at €92.24 per 150ml bottle through the French social security system.
  • ADV7103 for Cystinuria Pipeline extension of ADV7103 in development for the treatment of cystinuria, a rare inherited cystine transport disorder causing recurrent kidney stones. Granted FDA Orphan Drug Designation in March 2024.

Quantifiable outcome

  • European end-market sales of Sibnayal® surged 71% to €10.8 million in 2025
  • +3 more outcomes

Companies that use Advicenne

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Advicenne technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Advicenne partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered minor and core.

  • Primex Pharmaceuticals AGminorOEM/ Whitelabel/ Licensing Partner · 13 December 2024Agreement finalized December 2024 for previously sold drug candidate ADV6209 (for moderate sedation). Generates ongoing royalty income.
  • Avanzanite BiosciencecoreChannel Partner/ Reseller/ Distributor · 28 February 2023Distribution agreement completing European commercial coverage of Sibnayal®, specifically for Germany. Finalizes full European geographic footprint.
  • SPA (Società Prodotti Antibiotici)coreChannel Partner/ Reseller/ Distributor · 14 February 2023Exclusive distribution agreement for marketing of Sibnayal® in Italy, Spain, and Portugal. Strategic partnership for Southern European market coverage.
  • Taïba HealthcarecoreChannel Partner/ Reseller/ Distributor · 28 June 2022Commercialization agreement for Sibnayal® in Middle-East region. Enables patient access in Saudi Arabia (marketing authorization and reimbursement received July 2025) and UAE (January 2026).
  • FrostPharma ABcoreChannel Partner/ Reseller/ Distributor · 4 January 2022Exclusive distribution partnership for commercialization of Sibnayal™ in the Nordic region (Denmark, Norway, Sweden, Finland, Iceland). Enables market access in Nordic countries through established local pharmaceutical distribution.
  • Elaiapharm LundbeckcoreTechnology or Integration · 4 September 2019Long-term manufacturing supply agreement securing production of ADV7103. Ensures reliable supply chain for commercial production of Sibnayal®.
  • European Society for Paediatric Nephrology (ESPN)minorStrategic or Co-development Partner · 15 May 2018Partnership to improve patient care for distal Renal Tubular Acidosis (dRTA) in Europe. Aims to enhance knowledge and management of the disease through scientific collaboration.
  • DesitinminorOEM/ Whitelabel/ Licensing Partner · 20 February 2014License agreement on anti-epileptic Levidcen micro-granules for French market. Product authorized for marketing in France April 2015.

Scale indicators11 records

Recent moves9 records

Expansion highlights5 records

Advicenne competitors and assessment

Company assessment

Broad incumbents

  • BioMarin Pharmaceutical: Established US rare disease specialty pharma with a portfolio of orphan therapies across multiple indications. Comparable as a larger, commercially mature rare disease player pursuing similar regulatory and reimbursement pathways.
  • Ultragenyx Pharmaceutical: Commercial-stage rare disease biotech with multiple approved orphan therapies and a focus on smaller populations. Comparable in business model, regulatory pathway expertise, and commercial-stage rare disease focus.
  • Alexion / AstraZeneca Rare Disease: Global rare disease franchise within AstraZeneca with established renal and metabolic rare disease therapies (e.g., complement-mediated kidney disorders). Comparable as a broader incumbent that overlaps with Advicenne's nephrology rare disease focus.
  • Otsuka Pharmaceutical: Established Japanese pharmaceutical company that developed JYNARQUE (tolvaptan) for autosomal dominant polycystic kidney disease (ADPKD). Comparable as a large incumbent with a meaningful rare renal franchise overlapping Advicenne's nephrology focus.

Direct peers

  • Travere Therapeutics: US rare-disease specialty pharma with a focused rare kidney disease portfolio (FILSPARI for IgA nephropathy, sparsentan). Comparable to Advicenne as a small-cap rare renal player pursuing orphan indications and navigating similar commercial and regulatory milestones.
  • Arbor Pharmaceuticals: US specialty pharmaceutical company with products in nephrology and related therapeutic areas. Comparable as a smaller specialty pharma with focused renal/urology commercial offerings and similar distribution-driven commercial model.
  • Calliditas Therapeutics: Swedish specialty pharma that developed Tarpeyo, the first FDA-approved treatment for IgA nephropathy. Highly comparable as a small European-headquartered rare renal disease company commercializing an orphan kidney therapy in the US and EU.
  • Swedish Orphan Biovitrum (Sobi): Swedish-headquartered rare disease specialty pharma commercializing across Europe and the US. Comparable in business model (rare disease focus, European-listed, commercial-stage) and in serving similar small-population specialty indications.
  • Recordati Rare Diseases: The rare disease division of Recordati, focused on specialty and orphan therapies across multiple geographies. Comparable to Advicenne as a Europe-based specialty pharma commercializing orphan therapeutics via partner-driven distribution.

Emerging players

  • Chinook Therapeutics (Novartis): Rare kidney disease biotech (acquired by Novartis in 2023) that developed therapies for IgA nephropathy and other rare renal conditions. Comparable as a focused rare renal disease developer that pursued similar orphan nephrology indications.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Advicenne social profiles

Digital presence

Advicenne compliance and trust

Trust signal

Compliance2 records

Advicenne financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Advicenne leadership team

Management profile

Number of profiles

Profiles3 records

Advicenne subsidiaries and ownership

Company hierarchy

Subsidiaries5 records

Advicenne funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Advicenne M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Advicenne

What does Advicenne do?

Advicenne develops and commercializes pediatric-friendly specialty pharmaceutical products for rare renal diseases, with lead product Sibnayal® (ADV7103), a prolonged-release granule formulation combining potassium citrate and potassium bicarbonate approved in Europe and the UK for treating distal Renal Tubular Acidosis (dRTA) in children and adults. The portfolio also includes Likozam® (clobazam) for drug-resistant pediatric epilepsy, with pipeline expansion into cystinuria via ADV7103.

Is Advicenne a public or private company?

Advicenne is a public company. It is classified as public and is currently operating.

When was Advicenne founded?

Advicenne was founded in 2017. It employs 11 to 50 people.

Where is Advicenne based?

Advicenne is headquartered in Paris, France, in the Europe region.

How does Advicenne make money?

Four revenue lines are on record. Product Sales - Sibnayal® is the primary driver. The others are product Sales - Likozam®, royalties and out-licensing - Levidcen.

Who are Advicenne's main competitors?

Broad incumbents on record are BioMarin Pharmaceutical, Ultragenyx Pharmaceutical, Alexion / AstraZeneca Rare Disease and Otsuka Pharmaceutical. Direct peers are Travere Therapeutics, Arbor Pharmaceuticals, Calliditas Therapeutics, Swedish Orphan Biovitrum (Sobi) and Recordati Rare Diseases. Chinook Therapeutics (Novartis) is listed as an emerging player.

Does Advicenne have an API?

No public API is recorded for Advicenne.

What industry is Advicenne in?

Advicenne's product category is Specialty Pharmaceuticals - Rare Renal Disease Therapeutics. Its primary akta.pro industry code is HLAIAIAI, Rare Renal & Nephrology Disorder Therapies, with a secondary code of HLAKAHAL, Renal Nutrition & Kidney Dietetics Services. Its NAICS code is 621492 and its SIC code is 5122.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Pulse 2.0Advicenne Extends Cash Runway To 2028 With €1 Million Bond Financing And Strong Product SalesAdvicenne received €1 million in net cash from a bond financing with L1 Capital, extending its cash runway to 2028. The company held €1.55 million in cash as of June 30, 2026, and cited strong sales of its products. It also has an additional €1.2 million financing option available.Business Wire BlogAdvicenne Extends Its Cash Runway to 2028 Through Bond Financing and Strong Operational PerformanceAdvicenne received the remaining €1.0 million tranche of its bond financing, extending its cash runway to 2028 from the previously estimated Q2 2027. The company's cash position stood at €1.55 million as of 30 June 2026, supported by strong sales of its products.YahooAdvicenne Extends Its Cash Runway to 2028 Through Bond Financing and Strong Operational PerformanceAdvicenne received €1 million in net cash proceeds from a bond financing agreement with a fund managed by L1 Capital. The funding extended its cash runway to 2028, up from the previously estimated Q2 2027, supported by strong product sales and disciplined resource management.YahooAdvicenne Reports First Half Financial Results as of June 30, 2026, and Updates on Its ActivitiesAdvicenne reported a first-half 2026 net profit of €4.61 million, up from a €4.96 million loss in the same period of 2025. Net debt fell by nearly €6 million to €25.5 million, and cash and equivalents stood at €1.55 million. The company expects continued sales growth and a reduction in operating expenses in the second half.Business Wire BlogAdvicenne Reports First Half Financial Results as of June 30, 2026, and Updates on Its ActivitiesAdvicenne reported a first-half 2026 net profit of €4.61 million, up from a €4.96 million loss in the same period of 2025. Net debt fell by nearly €6 million to €25.5 million, and cash and equivalents stood at €1.55 million. The company expects continued sales growth and a reduction in operating expenses in the second half.MarketScreenerAdvicenne Withdraws US Application for Distal Renal Tubular Acidosis DrugAdvicenne, a pharmaceutical company, has one product in clinical development: ADV7103 for distal renal tubular acidosis and cystinuria. The company also focuses on neglected neurological and nephrological diseases, mostly among children.YahooAdvicenne decides to withdraw its ADV7103 New Drug Application in the USAAdvicenne announced the voluntary withdrawal of its New Drug Application for ADV7103 (Sibnayal) in the USA, citing CMC-related work that cannot be completed within the current review cycle. The drug is approved in the EU, UK, KSA, and UAE, and the company will host a shareholder webinar on September 1st.Business Wire BlogAdvicenne decides to withdraw its ADV7103 New Drug Application in the USAAdvicenne, a Paris-based specialty pharmaceutical company, announced the voluntary withdrawal of its New Drug Application for ADV7103 (Sibnayal) in the treatment of primary distal renal tubular acidosis in the USA. The company said additional chemistry, manufacturing and controls work was required beyond the current review cycle. ADV7103 is approved in the EU, UK, Saudi Arabia and the UAE.The Pharma LetterAdvicenne wins Spanish reimbursement for Sibnayal in dRTAFrench pharma company Advicenne has secured reimbursement approval in Spain for Sibnayal, a prolonged-release combination of potassium citrate and potassium bicarbonate used to treat distal renal tubular acidosis (dRTA). The reimbursed prices in Spain are set at 409.84 euros for the 24 mEq dose and 136.62 euros for the 8 mEq dose. This marks a commercial milestone for Advicenne's flagship product in a key European market, following the drug's prior approvals in other regions.MorningstarAdvicenne Announces the Reimbursement of Sibnayal® for the Treatment of dRTA in SpainAdvicenne announced that Sibnayal is now reimbursed in Spain for distal renal tubular acidosis, with prices of €409.84 and €136.62 for two strengths. The reimbursement follows an early access program, and the CEO called it a milestone in Europe's largest market.